Osimertinib in lung cancer: Added benefit not proven

Posted by on June 20, 2016 3:20 pm
Categories: health

Due to a lack of studies of direct comparisons the manufacturer subsequently submitted historical comparisons, but the visible effects were not large enough for conclusions on added benefit.

Leave a Reply

Your email address will not be published. Required fields are marked *